| COVID-19 and healthcare impacts | Lifetime | 11 | GB 3 | 99.53 |
| Vascular Procedures and Complications | Lifetime | 15 | GB 1 | 99.63 |
| Acute Myocardial Infarction Research | Lifetime | 153 | GB 9 | 99.49 |
| Coronary Interventions and Diagnostics | Lifetime | 168 | GB 6 | 99.46 |
| Central Venous Catheters and Hemodialysis | Lifetime | 134 | GB 4 | 98.81 |
| Heart Failure Treatment and Management | Lifetime | 254 | GB 21 | 99.04 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 439 | GB 34 | 98.74 |
| Chronic Disease Management Strategies | Lifetime | 186 | GB 38 | 98.50 |
| Cardiac, Anesthesia and Surgical Outcomes | Lifetime | 826 | GB 90 | 98.43 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 267 | GB 19 | 98.66 |
| Cardiac Imaging and Diagnostics | Lifetime | 914 | GB 62 | 98.64 |
| Peripheral Artery Disease Management | Lifetime | 382 | GB 30 | 97.67 |
| Cardiovascular Issues in Pregnancy | Lifetime | 267 | GB 30 | 97.58 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 164 | GB 5 | 96.22 |
| Cardiac Health and Mental Health | Lifetime | 590 | GB 50 | 96.32 |
| Healthcare cost, quality, practices | Lifetime | 348 | GB 50 | 95.76 |
| Cardiovascular Health and Risk Factors | Lifetime | 810 | GB 56 | 91.09 |
| Sex and Gender in Healthcare | Lifetime | 302 | GB 17 | 85.71 |
| Pericarditis and Cardiac Tamponade | Lifetime | 991 | GB 58 | 82.63 |
| Social Media in Health Education | Lifetime | 966 | GB 75 | 80.46 |
| Case Reports on Hematomas | Lifetime | 486 | GB 22 | 78.65 |
| Medical Coding and Health Information | Lifetime | 665 | GB 112 | 72.98 |
| Takotsubo Cardiomyopathy and Associated Phenomena | Lifetime | 967 | GB 56 | 73.03 |
| COVID-19 and healthcare impacts | 2021-2025 | 5 | GB 3 | 99.72 |
| Acute Myocardial Infarction Research | 2021-2025 | 4 | GB 1 | 99.88 |
| Cardiac Imaging and Diagnostics | 2021-2025 | 44 | GB 9 | 99.51 |
| Coronary Interventions and Diagnostics | 2021-2025 | 39 | GB 4 | 99.30 |
| Chronic Disease Management Strategies | 2021-2025 | 31 | GB 15 | 98.36 |
| Cardiac Health and Mental Health | 2021-2025 | 33 | GB 4 | 97.89 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 117 | GB 22 | 98.39 |
| Healthcare cost, quality, practices | 2021-2025 | 18 | GB 4 | 97.15 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 46 | GB 5 | 98.48 |
| Cardiac, Anesthesia and Surgical Outcomes | 2021-2025 | 170 | GB 17 | 97.96 |
| Venous Thromboembolism Diagnosis and Management | 2021-2025 | 127 | GB 5 | 98.47 |
| Heart Failure Treatment and Management | 2021-2025 | 104 | GB 12 | 98.79 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 28 | GB 2 | 97.79 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 54 | GB 2 | 96.58 |
| Cardiovascular Issues in Pregnancy | 2021-2025 | 57 | GB 6 | 96.63 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 406 | GB 30 | 97.21 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 432 | GB 26 | 96.90 |
| Cardiac Valve Diseases and Treatments | 2021-2025 | 491 | GB 18 | 96.78 |
| Acute Ischemic Stroke Management | 2021-2025 | 629 | GB 28 | 95.59 |
| Infective Endocarditis Diagnosis and Management | 2021-2025 | 373 | GB 8 | 95.27 |
| Cardiac Structural Anomalies and Repair | 2021-2025 | 543 | GB 12 | 94.20 |
| Health disparities and outcomes | 2021-2025 | 677 | GB 101 | 92.12 |
| Vascular Procedures and Complications | 2021-2025 | 252 | GB 7 | 91.36 |
| Frailty in Older Adults | 2021-2025 | 579 | GB 53 | 91.34 |
| Cerebrovascular and Carotid Artery Diseases | 2021-2025 | 871 | GB 32 | 91.49 |
| Sex and Gender in Healthcare | 2021-2025 | 52 | GB 2 | 89.09 |
| Healthcare Policy and Management | 2021-2025 | 400 | GB 19 | 89.60 |
| Mechanical Circulatory Support Devices | 2021-2025 | 823 | GB 23 | 91.17 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 686 | GB 35 | 84.61 |
| Peripheral Artery Disease Management | 2021-2025 | 866 | GB 54 | 83.64 |
| Global Public Health Policies and Epidemiology | 2021-2025 | 960 | GB 130 | 74.84 |
| Health Promotion and Cardiovascular Prevention | 2021-2025 | 199 | GB 24 | 74.70 |
| Gout, Hyperuricemia, Uric Acid | 2021-2025 | 448 | GB 11 | 76.62 |
| Cardiac and Coronary Surgery Techniques | 2021-2025 | 514 | GB 40 | 74.33 |
| Cardiac tumors and thrombi | 2021-2025 | 699 | GB 23 | 72.07 |
| Takotsubo Cardiomyopathy and Associated Phenomena | 2021-2025 | 209 | GB 17 | 71.65 |
| Pericarditis and Cardiac Tamponade | 2021-2025 | 275 | GB 8 | 69.94 |
| Kawasaki Disease and Coronary Complications | 2021-2025 | 881 | GB 39 | 68.57 |
| Coronary Artery Anomalies | 2021-2025 | 873 | GB 28 | 66.41 |
| Health and Medical Research Impacts | 2021-2025 | 711 | GB 51 | 66.69 |
| Case Reports on Hematomas | 2021-2025 | 157 | GB 8 | 63.37 |
| Potassium and Related Disorders | 2021-2025 | 891 | GB 53 | 55.40 |
